This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Has Abiomed (ABMD) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Abiomed (ABMD) and Armata Pharmaceuticals, Inc. (ARMP) have performed compared to their sector so far this year.
Wall Street Analysts Believe Armata Pharmaceuticals, Inc. (ARMP) Could Rally 47%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Armata Pharmaceuticals, Inc. (ARMP) points to a 46.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
What Makes Armata Pharmaceuticals, Inc. (ARMP) a New Buy Stock
by Zacks Equity Research
Armata Pharmaceuticals, Inc. (ARMP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Armata Pharmaceuticals, Inc. (ARMP) delivered earnings and revenue surprises of 15.38% and 23.25%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Armata Pharmaceuticals, Inc. (ARMP) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Armata Pharmaceuticals, Inc. (ARMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Armata Pharmaceuticals, Inc. (ARMP) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Armata Pharmaceuticals, Inc. (ARMP) delivered earnings and revenue surprises of 0.00% and 42.44%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Armata Pharmaceuticals, Inc. (ARMP) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Armata Pharmaceuticals, Inc. (ARMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Armata's AP-PA02 Gets IND Clearance by FDA to Initiate Study
by Zacks Equity Research
Armata's (ARMP) AP-PA02 IND application gets clearance from the FDA to initiate a phase Ib/IIa study for the treatment of Pseudomonas aeruginosa infections.
Company News for Jun 18, 2020
by Zacks Equity Research
Companies in the news are: WATT, ARMP, MGEN, CEMI
Company News For Jan 29, 2020
by Zacks Equity Research
Companies In The News Are: ARMP, GGG, MMM and OBCI